Kalamazoo hires longtime Grand Rapids parks and recreation director
KALAMAZOO, Mich. (WOOD) — The city of Kalamazoo has hired a new deputy city manager, who comes to Kalamazoo from Grand Rapids.
City leaders on Monday announced the hiring of David Marquardt. He has been Grand Rapids' director of parks and recreation since 2015.
'David leaves us with a capable department of dedicated employees, a thriving parks system and numerous community partnerships,' stated Grand Rapids City Manager Mark Washington. 'I appreciate his service and wish him well in this management role for our neighbors in Kalamazoo.'
As deputy city manager, Marquardt will be responsible for departments like parks and recreation and public services. He will also oversee communication projects.
In a statement, Marquardt said he was 'genuinely thrilled' to be joining the City Manager's Office.
'Kalamazoo has the charm of a smaller community as well as many amenities found in larger cities,' he said. 'With its thriving college and university institutions as well as its numerous well-known businesses and corporations, I am looking forward to contributing to and uplifting the strengths of Kalamazoo's community fabric.'
Marquardt is set to leave his position in Grand Rapids on July 4 and join the Kalamazoo City Manager's Office on July 7. Leaders in Grand Rapids say they're working on a plan for interim leadership.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District Judge James Selna ordered the company to pay three times the $147 million in damages awarded by the jury, as permitted under antitrust regulations. This sum does not include legal fees or other related costs. Daniel Vukelich, CEO of the Association of Medical Device Reprocessors, described the decision as 'a seismic result.' In response, a Johnson & Johnson (NYSE:JNJ) spokesperson said the company intends to appeal the verdict but will comply with the court's decision and any required relief for now. The spokesperson added, 'We strongly disagree with the jury's verdict and believe it will not withstand appellate review.' Innovative Health sued Johnson & Johnson (NYSE:JNJ)'s Biosense Webster in 2019, claiming the company used its market power to block hospitals from using reprocessed heart-mapping catheters by tying support for its Carto 3 system to purchases of its own products. A jury found Johnson & Johnson (NYSE:JNJ) violated antitrust laws by withholding support for the reprocessed devices. AMDR's CEO said the ruling signals that anti-competitive tactics against reprocessing won't be tolerated. The case was heard in the U.S. District Court for the Central District of California. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
8 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Trump is under water on some of his top issues — including immigration, poll shows
President Donald Trump is under water on some of his most favorable issues — immigration and the economy — according to a new Quinnipiac University poll released Wednesday. The poll shows Trump's approval rating at 38 percent among registered voters, a three point drop from April. He's also losing support on subjects that were crucial to his November victory. On immigration — an issue that the president hammered on the campaign trail — Trump's approval rating dropped five points from April, to 43 percent. His already low approval rating on the economy did not budge, remaining at 40 percent. The results show a majority of voters, 54 percent, disapprove of Trump's handling of the issue. The poll surveyed 1,265 self-identified registered voters from June 5-9, and has a margin of error of plus or minus 2.8 percent. The results come as Trump's approval has been steadily picking up since it dropped significantly in April, according to RealClearPolitics' polling average. The negative polling did not stop at the president himself. A majority of the voters polled also had objections to his premier piece of legislation, the 'big, beautiful bill' making its way through Congress. Fifty-three percent of the voters polled did not support the legislation. Divided among party lines, 67 percent of Republicans supported, while 89 percent of Democrats and 57 percent of independents opposed it. On Medicaid funding, an issue that has become Democratic messaging priority, 47 percent of those surveyed thought funding should increase, while 40 percent think it should stay about the same, and just 10 percent think federal funding should decrease. The bill as passed by the House is estimated to end Medicaid coverage for millions of people. Quinnipiac also asked voters what they think of billionaire Elon Musk, and his approval rating is crashing among Republicans following his very public breakup with Trump. Among Republicans, 62 percent had a favorable view of Musk, a 16 point drop from April. But while Trump's approval languishes, it's not clear Democrats will be able to take advantage of it. A vast majority of voters — 70 percent — disapprove of the way Democrats in Congress are doing their jobs, while 20 percent approved. That's 12 points lower than how voters viewed Republicans in the survey.
